久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Onyx
Onyx
Onyx Onyx

美國Onyx Pharmaceuticals, Inc.
2009 Onyx將以8.51億美元收購抗癌藥開發商Proteolix

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. Our approved product, Nexavar? (sorafenib) tablets, is a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis. Nexavar is approved in more than 80 countries for the treatment of patients with unresectable liver cancer and in more than 90 countries for the treatment of patients with advanced kidney cancer.

As part of a broad clinical development program, Nexavar is also being evaluated in multiple Phase 3 and Phase 2 trials as a single agent or combination treatment in a wide range of cancers, including lung cancer, thyroid cancer, breast cancer, colorectal cancer, ovarian cancer, and as an adjuvant therapy for liver cancer and kidney cancer. Nexavar is being developed and marketed in collaboration with Bayer HealthCare Pharmaceuticals.

Beyond Nexavar, Onyx is pursuing a proteasome inhibition development program. The proteasome has been validated as an important clinical target in cancer, and Onyx is developing next-generation proteasome inhibitors with a high degree of selectivity, with the goal of increasing therapeutic efficacy and reducing side effects.

The lead product candidate in this program is carfilzomib, a selective, next-generation compound that is currently in multiple clinical trials to evaluate its safety and efficacy for the treatment of patients with multiple myeloma and solid tumors. Among these studies, enrollment has been completed in a Phase 2b monotherapy trial evaluating carfilzomib in patients with relapsed and refractory multiple myeloma, the pivotal trial that could support a new drug application (NDA) filing by the end of 2010 and potential accelerated approval in 2011.

In addition to carfilzomib, the proteasome inhibitor development program includes ONX 0912 (formerly PR-047), an oral proteasome inhibitor that is expected to enter Phase 1 testing in hematologic and solid tumors in 2010, and ONX 0914 (formerly PR-957), an immunoproteasome inhibitor with activity in preclinical models of autoimmune disorders.

Onyx has also established a development pipeline of anticancer compounds at various stages of clinical testing. Onyx is developing ONX 0801, a targeted alpha-folate inhibitor that recently entered into Phase 1 testing. Onyx also has options to license the rights to two Janus Kinase 2 (JAK2) inhibitors: ONX 0803, in Phase 1 studies to treat primary myelofibrosis and lymphoid malignancies, and ONX 0805, currently in preclinical development. PD 332991, an oral, small molecule cyclin-dependent kinase 4 (CDK4) inhibitor, resulted from a collaboration with Warner-Lambert Company, now Pfizer. Pfizer is responsible for all product development activities and costs. In exchange, Onyx will receive milestone payments and a single-digit royalty on any worldwide sales of the product.

Onyx common stock is traded on the Nasdaq Global Market under the symbol ONXX.

 

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 亚洲欧美日本在线 | 国内精品视频免费观看 | 欧美精品国产精品 | 天码毛片一区二区三区入口 | 国产精品久久久久久久久久免费 | 国产传媒一区二区三区四区五区 | 在线亚洲一区 | 国产美女精品久久久久中文 | 国产成人久久久精品毛片 | 欧美精品一区二区三区免费播放 | 国产在线视频资源 | 久久亚洲精选 | 亚洲一区影院 | 一区二区三区日韩 | 不卡二区| 成人a毛片免费视频观看 | 日韩在线二区 | 久久久久久久久久久9精品视频 | 国产va精品免费观看 | 国产精品电影一区二区三区 | 国产免费高清视频在线观看不卡 | 欧美日本日韩aⅴ在线视频 欧美日韩91 | 久久99精品一区二区三区 | 欧美国产免费 | 一级毛片一级毛片一级级毛片 | 日韩亚洲国产综合久久久 | 亚洲综合无码一区二区 | 99国内精品久久久久久久 | 中文字幕日韩一区二区三区不卡 | 日韩在线一区二区三区免费视频 | 另类区| 日韩欧美高清 | 日韩 亚洲 制服 欧美 综合 | 欧美日韩亚洲高清不卡一区二区三区 | 免费国产va在线观看视频 | 久久精品国产999久久久 | 日韩一区二区久久久久久 | 日本亚洲国产精品久久 | 全部费免一级毛片不收费 | 亚洲第一区在线观看 | www.亚洲欧美|